Compare Charles River Laboratories Intl. Inc (CRL) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Meta Platforms Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while Meta Platforms Inc trades at $724.45 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 129.3× Charles River Laboratories Intl. Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Meta Platforms Inc for 127 Days on average.
| CRL | META | |
|---|---|---|
Market Cap | $14.23B | $1.84T |
Volume | 1,176,885 | 15,887,049 |
Sector | Health | Media |
52-Week High | $310.77 | $777.59 |
52-Week Low | $149.93 | $525.72 |
Typical Hold Time | 33 Days | 127 Days |
Enterprise Value | $17.06B | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
META trades at $723.54, up 0.31% on the day, with a bullish technical signal from moving averages and support at $714. The company reported strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a $21B deal with CoreWeave, driving positive sentiment.
The outlook is positive with an 80% analyst buy rating and a consensus price target of $781, but risks include ongoing youth addiction lawsuits and high capital expenditures. Revenue is projected to grow to $228.2B in 2026, supporting long-term growth despite near-term legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
